Even after its latest sharp fall, the drugmaker’s stock price assumes wild successes.

A personalised cancer vaccine developed by Moderna and Merck shows promise in reducing melanoma metastasis risk by 38% using ...

A study of a personalized vaccine combined with an existing immunotherapy found the treatment helped patients with melanoma avoid cancer recurrence. The combination trains the patient's immune system ...

When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial<a class="excerpt-read-more" href=" More ...

Merck KGaA's $1.3 billion cash purchase of Silence Therapeutics — at roughly a 130% premium — caps a near-death turnaround that former CEO ...

When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each ...

Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma ...

Moderna launched its coronavirus vaccine in early pandemic days and saw revenue and stock performance skyrocket. As demand ...

Six melanoma specialists described Moderna and Merck's personalized cancer vaccine results as clinically meaningful and ...

The vaccine, called intismeran, is tailored to each patient’s tumour. The findings, which measured recurrence risk over two ...

Moderna aur Merck ke shares gire jab vaccine trial data ne sirf **42%** recurrence reduction dikhaya. Investors ki badhi ...